Established therapeutic strategies, including RAAS blockers, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Glucagon-like Peptide-1 receptor agonists (GLP-1 RA), non-steroidal mineralocorticoid antagonists (ns-MRAs), and their impact on CKD progression are highlighted. The gene discussed is SLC5A2; the disease is chronic kidney disease.